Keytruda's Third-Line Gastric Cancer Indication Should Go, US FDA Panel Says
Executive Summary
Citing changing therapeutic landscape and doubts about utility of checkpoint inhibitor monotherapy in this setting, advisory committee votes 6-2 against maintaining PD-1 inhibitor’s accelerated approval for third-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma.
You may also be interested in...
Keeping Track: US FDA Approval Of Jazz Rylaze Addresses Shortage; MediWound, Cyclopharm Receive CRLs
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Keytruda May Stay Competitive In Gastric Cancer Despite Losing Third-Line Claim
While Opdivo’s first-line approval has altered the treatment landscape, Keytruda may expand its presence there in the next few years with new indications.
‘Future Protect': Shoring Up Clinical Programs Against Changes In Standard Of Care
Contract research organization leaders weigh in on how to avoid some recent pitfalls seen at US FDA advisory committee panels.